(Total Views: 799)
Posted On: 10/17/2020 3:34:51 PM
Post# of 151830
Re: thriftycents #61777
Maraviroc downregulates MCP-1. I haven't seen any results for leronlimab but TNF-a, IL-1 and IFN-y upregulate MCP-1 and leronlimab downregulates all 3 so there should be a significant reduction in MCP-1.
CCL5 (RANTES) does not bind to CCR2. Which suggests that cenicriviroc has an imperfect blockade of CCR5 allowing CCL5 binding and the upregulation of the three other chemokines. Even worse news for cenicriviroc if true,
After I wrote that I decided to track things down to see if what I said was true. A bit backward way to do things but I was correct. Who's bright idea was it that cenicriviroc would be a good candidate.
https://ascpt.onlinelibrary.wiley.com/doi/ful.../cts.12397
CCL5 (RANTES) does not bind to CCR2. Which suggests that cenicriviroc has an imperfect blockade of CCR5 allowing CCL5 binding and the upregulation of the three other chemokines. Even worse news for cenicriviroc if true,
After I wrote that I decided to track things down to see if what I said was true. A bit backward way to do things but I was correct. Who's bright idea was it that cenicriviroc would be a good candidate.
Quote:
CCL5 increased significantly during cenicriviroc treatment in matched controls(aka placebo group).
To determine whether the reciprocal increase in CCL2, CCL4, and CCL5 levels associated with the potent CCR2 and CCR5 blockade increased systemic inflammation, levels of proinflammatory cytokines were measured. IL‐6, TNF‐α, and IL‐1β levels did not change significantly in any group during cenicriviroc treatment
https://ascpt.onlinelibrary.wiley.com/doi/ful.../cts.12397
(9)
(0)Scroll down for more posts ▼
